PURPOSE: Women with metastatic triple negative breast cancer (TNBC) can have a poor prognosis with treatment limited to cytotoxic chemotherapy. The identification of effective therapies that may limit exposure to cytotoxic chemotherapy and lead to prolonged survival is an unmet medical need. We tested an inhibitor of the epidermal growth factor receptor, panitumumab in combination with chemotherapy. METHODS: We conducted a single arm clinical trial in women with metastatic or locally advanced TNBC to paclitaxel 80 mg/m2 and carboplatin AUC of 2 on days 1, 8, and 15 and panitumumab 6 mg/kg on days 1 and 15 for a cycle length of 28 days. The objectives were to evaluate the response rate and safety of the combination in comparison to historical controls. RESULTS: Fourteen patients with TNBC were enrolled with a median age of 53 years. The majority of women were African American (64.3%) with visceral metastasis (64.2%). Hematologic toxicities, particularly neutropenia and thrombocytopenia, were a major cause of missed chemotherapy and delayed treatment in this study. The overall response rate (complete and partial response) of the 13 evaluable patients was 46%. The median time to best response was 2.4 months and the median time to disease progression was 3.6 months. We were able to perform the PAM50 analysis on tumors from 7 of our subjects. All the samples tested clustered within the basal-like subtype. CONCLUSIONS: In our experience the response rate of carboplatin, paclitaxel and panitumumab was consistent with other reports of response for cytotoxic chemotherapy in metastatic TNBC.
PURPOSE:Women with metastatic triple negative breast cancer (TNBC) can have a poor prognosis with treatment limited to cytotoxic chemotherapy. The identification of effective therapies that may limit exposure to cytotoxic chemotherapy and lead to prolonged survival is an unmet medical need. We tested an inhibitor of the epidermal growth factor receptor, panitumumab in combination with chemotherapy. METHODS: We conducted a single arm clinical trial in women with metastatic or locally advanced TNBC to paclitaxel 80 mg/m2 and carboplatin AUC of 2 on days 1, 8, and 15 and panitumumab 6 mg/kg on days 1 and 15 for a cycle length of 28 days. The objectives were to evaluate the response rate and safety of the combination in comparison to historical controls. RESULTS: Fourteen patients with TNBC were enrolled with a median age of 53 years. The majority of women were African American (64.3%) with visceral metastasis (64.2%). Hematologic toxicities, particularly neutropenia and thrombocytopenia, were a major cause of missed chemotherapy and delayed treatment in this study. The overall response rate (complete and partial response) of the 13 evaluable patients was 46%. The median time to best response was 2.4 months and the median time to disease progression was 3.6 months. We were able to perform the PAM50 analysis on tumors from 7 of our subjects. All the samples tested clustered within the basal-like subtype. CONCLUSIONS: In our experience the response rate of carboplatin, paclitaxel and panitumumab was consistent with other reports of response for cytotoxic chemotherapy in metastatic TNBC.
Entities:
Keywords:
AUC, area under the curve; CR, complete response; EGFR, Epidermal growth factor inhibitor; FISH, Fluorescence in situ hybridization; Hgb, hemoglobin; IHC, immunohistochemistry; IRB, Institutional Review Board; Mg/dl, milligram/deciliter; Mg/kg, milligram/kilogram; PD, progressive disease; PR, partial response; RECIST, response evaluation in sold tumors; TNBC, triple negative breast cancer; epidermal growth factor inhibitor; g/dl, grams/deciliter; metastatic breast cancer; pacliataxel carboplatin; triple negative breast cancer
Authors: L Staudacher; P H Cottu; V Diéras; A Vincent-Salomon; M N Guilhaume; L Escalup; T Dorval; P Beuzeboc; L Mignot; J Y Pierga Journal: Ann Oncol Date: 2010-10-05 Impact factor: 32.976
Authors: Torsten O Nielsen; Forrest D Hsu; Kristin Jensen; Maggie Cheang; Gamze Karaca; Zhiyuan Hu; Tina Hernandez-Boussard; Chad Livasy; Dave Cowan; Lynn Dressler; Lars A Akslen; Joseph Ragaz; Allen M Gown; C Blake Gilks; Matt van de Rijn; Charles M Perou Journal: Clin Cancer Res Date: 2004-08-15 Impact factor: 12.531
Authors: Shirin Khambata-Ford; Christopher R Garrett; Neal J Meropol; Mark Basik; Christopher T Harbison; Shujian Wu; Tai W Wong; Xin Huang; Chris H Takimoto; Andrew K Godwin; Benjamin R Tan; Smitha S Krishnamurthi; Howard A Burris; Elizabeth A Poplin; Manuel Hidalgo; Jose Baselga; Edwin A Clark; David J Mauro Journal: J Clin Oncol Date: 2007-08-01 Impact factor: 44.544
Authors: Joel S Parker; Michael Mullins; Maggie C U Cheang; Samuel Leung; David Voduc; Tammi Vickery; Sherri Davies; Christiane Fauron; Xiaping He; Zhiyuan Hu; John F Quackenbush; Inge J Stijleman; Juan Palazzo; J S Marron; Andrew B Nobel; Elaine Mardis; Torsten O Nielsen; Matthew J Ellis; Charles M Perou; Philip S Bernard Journal: J Clin Oncol Date: 2009-02-09 Impact factor: 44.544
Authors: José Baselga; Patricia Gómez; Richard Greil; Sofia Braga; Miguel A Climent; Andrew M Wardley; Bella Kaufman; Salomon M Stemmer; António Pêgo; Arlene Chan; Jean-Charles Goeminne; Marie-Pascale Graas; M John Kennedy; Eva Maria Ciruelos Gil; Andreas Schneeweiss; Angela Zubel; Jutta Groos; Helena Melezínková; Ahmad Awada Journal: J Clin Oncol Date: 2013-06-03 Impact factor: 44.544
Authors: Robert Pirker; Jose R Pereira; Aleksandra Szczesna; Joachim von Pawel; Maciej Krzakowski; Rodryg Ramlau; Ihor Vynnychenko; Keunchil Park; Chih-Teng Yu; Valentyn Ganul; Jae-Kyung Roh; Emilio Bajetta; Kenneth O'Byrne; Filippo de Marinis; Wilfried Eberhardt; Thomas Goddemeier; Michael Emig; Ulrich Gatzemeier Journal: Lancet Date: 2009-05-02 Impact factor: 79.321
Authors: Cynthia X Ma; Matthew J C Ellis; Gina R Petroni; Zhanfang Guo; Shi-Rong Cai; Christine E Ryan; A Craig Lockhart; Michael J Naughton; Timothy J Pluard; Christiana M Brenin; Joel Picus; Allison N Creekmore; Tibu Mwandoro; Erin R Yarde; Jerry Reed; Mark Ebbert; Philip S Bernard; Mark Watson; Laurence A Doyle; Janet Dancey; Helen Piwnica-Worms; Paula M Fracasso Journal: Breast Cancer Res Treat Date: 2012-12-15 Impact factor: 4.872
Authors: Therese Sorlie; Robert Tibshirani; Joel Parker; Trevor Hastie; J S Marron; Andrew Nobel; Shibing Deng; Hilde Johnsen; Robert Pesich; Stephanie Geisler; Janos Demeter; Charles M Perou; Per E Lønning; Patrick O Brown; Anne-Lise Børresen-Dale; David Botstein Journal: Proc Natl Acad Sci U S A Date: 2003-06-26 Impact factor: 12.779
Authors: Naoko Matsuda; Xiaoping Wang; Bora Lim; Savitri Krishnamurthy; Ricardo H Alvarez; Jie S Willey; Charla A Parker; Juhee Song; Yu Shen; Jianhua Hu; Wenhui Wu; Nan Li; Gildy V Babiera; James L Murray; Banu K Arun; Abenaa M Brewster; James M Reuben; Michael C Stauder; Chad M Barnett; Wendy A Woodward; H T Carisa Le-Petross; Anthony Lucci; Sarah M DeSnyder; Debu Tripathy; Vicente Valero; Naoto T Ueno Journal: JAMA Oncol Date: 2018-09-01 Impact factor: 31.777
Authors: Karima Oualla; Heba M El-Zawahry; Banu Arun; James M Reuben; Wendy A Woodward; Heba Gamal El-Din; Bora Lim; Nawfel Mellas; Naoto T Ueno; Tamer M Fouad Journal: Ther Adv Med Oncol Date: 2017-06-13 Impact factor: 8.168
Authors: Hui Liu; Marcia N Paddock; Haibin Wang; Charles J Murphy; Renee C Geck; Adrija J Navarro; Gerburg M Wulf; Olivier Elemento; Volker Haucke; Lewis C Cantley; Alex Toker Journal: Cancer Discov Date: 2020-06-08 Impact factor: 38.272